Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalCardiologyHeart FailureTrial Update

HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management

The HEARTFELT study could significantly influence heart failure management through enhanced remote monitoring, potentially reducing hospitalizations. Pharma companies must stay informed about the study's outcomes as they may necessitate adjustments in their product strategies and competitive positioning.

Published: June 20, 2026
Updated: June 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiology / Heart Failure
Company: pharma companies with heart failure portfolios
Asset: HEARTFELT
Trial SummaryCLN

Phase III

Cardiology / Heart Failure

Status

Active

Sponsor

pharma companies with heart failure portfolios

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

The HEARTFELT study could significantly influence heart failure management through enhanced remote monitoring, potentially reducing hospitalizations. Pharma companies must stay informed about the study's outcomes as they may necessitate adjustments in their product strategies and competitive positioning.

Why it matters

The HEARTFELT study could significantly influence heart failure management through enhanced remote monitoring, potentially reducing hospitalizations. Pharma companies must stay informed about the study's outcomes as they may necessitate adjustments in their product strategies and competitive positioning.

What changed

Trial Update

Analysis

The HEARTFELT study is assessing the safety and effectiveness of a remote patient monitoring device for heart failure patients.

The HEARTFELT study could significantly influence heart failure management through enhanced remote monitoring, potentially reducing hospitalizations. Pharma companies must stay informed about the study's outcomes as they may necessitate adjustments in their product strategies and competitive positioning.

Monitor the study's progress and results regarding safety and effectiveness, as well as its impact on hospitalization rates.

Related companies & assets

Companies

  • pharma companies with heart failure portfolios →

Assets

  • HEARTFELT →
  • heart failure patients →

Sources & Humanexa intelligence

Source links

  • HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management ↗

Related Humanexa pages

  • HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management →

Related signals

Trial SummaryCLN

Phase III

Gastroenterology / Ulcerative Colitis

Status

Active

Sponsor

Eli Lilly

Signal Score

8.2

Clinicalhigh signal

Eli Lilly's LY4268989 Study with Mirikizumab in Ulcerative Colitis Underway

A clinical trial is evaluating the safety and effectiveness of LY4268989 co-administered with mirikizumab in adults with moderately to severely active ulcerative colitis.

June 21, 2026Read signal →
Trial SummaryCLN

Phase III

Neurology / Multiple System Atrophy

Status

Active

Sponsor

Teva

Signal Score

8.2

Clinicalhigh signal

Teva's TEV-56286 Trial for Multiple System Atrophy Underway

Teva is conducting a trial to evaluate the efficacy and safety of TEV-56286 in adults with Multiple System Atrophy.

June 21, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.